| EX0724 FOUNDATIONONE CDX (F1CDX) |
| Specimen: |
Submit formalin-fixed paraffin-embedded Tissue Block. Block should have at least 10% tumor tissue. Duly filled FoundationOne Consent Form AND Third Party Authorisation Form is mandatory. Doctors’ prescription, Histopathology report & authorization form in the name of caregiver for report collection is also required. Ship at room temperature. |
| Stability: |
| Room |
Refrigerated |
Frozen |
| NA |
NA |
NA |
|
| Method: |
Next-Generation Sequencing |
| Comment: |
|
| Report: |
Contact us to know the TAT. |
| Usage: |
FoundationOne®CDx (F1CDx) is an NGS-based in vitro diagnostic device that uses targeted high throughput hybridization-based capture technology to detect substitutions, insertion & deletion alterations (indels), copy number alterations (CNAs) in 324 genes. Select gene rearrangements as well as genomic signatures including tumor mutational burden (bTMB) & microsatellite instability (MSI) are also reported. The test is intended to be used as a companion diagnostics to identify patients who may benefit from treatment with targeted therapies. Additionally, tumor mutation profiling provides guidelines to oncologists for the treatment of patients with solid malignant neoplasms. This test is also used for the detection of genomic loss of heterozygosity (LOH) in ovarian tumors. Positive homologous recombination deficiency (HRD) in ovarian cancer patients is associated with improved progression-free survival from Rubraca (Rucaparib) maintenance therapy. |
| Doctor Specialty: |
Oncologist |
| Disease: |
Cancer |
| Components: |
*324 genes *MSI *TMB *LOH (Ovarian) |
| Courier Charges: |
|
| Home Collection: |
Available (*T&C Apply) |
| Department: |
MOLECULAR DIAGNOSTICS |
| Pre Test Information: |
A duly filled FoundationOne Consent Form AND Third Party Authorisation Form is mandatory. Doctors’ prescription, Histopathology report & authorization form in the name of caregiver for report collection is also required. |
Reviews
There are no reviews yet.